BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 8900758)

  • 1. Recombinant human erythropoietin treatment of anemic cancer patients.
    Henry DH
    Cancer Pract; 1996; 4(4):180-4. PubMed ID: 8900758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erythropoietin therapy in cancer patients.
    Doweiko JP; Goldberg MA
    Oncology (Williston Park); 1991 Aug; 5(8):31-7; discussion 38, 43-4. PubMed ID: 1834151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer-related anemia: its causes and characteristics.
    Spivak JL
    Semin Oncol; 1994 Apr; 21(2 Suppl 3):3-8. PubMed ID: 8202724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EPO in cancer anemia: benefits and potential risks.
    Milano M; Schneider M
    Crit Rev Oncol Hematol; 2007 May; 62(2):119-25. PubMed ID: 17197190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical application of recombinant erythropoietin in anemic cancer patients.
    Henry DH
    Hematol Oncol Clin North Am; 1994 Oct; 8(5):961-73. PubMed ID: 7852218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant human erythropoietin and the anemia of multiple myeloma.
    Barlogie B; Beck T
    Stem Cells; 1993 Mar; 11(2):88-94. PubMed ID: 8457789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant human erythropoietin for the treatment of anemia in patients with advanced cancer.
    Henry DH
    Semin Hematol; 1993 Oct; 30(4 Suppl 6):12-6. PubMed ID: 8153671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy.
    Henry DH; Brooks BJ; Case DC; Fishkin E; Jacobson R; Keller AM; Kugler J; Moore J; Silver RT; Storniolo AM; Abels RI; Gordon DS; Nelson R; Larholt K; Bryant E; Rudnick S
    Cancer J Sci Am; 1995; 1(4):252-60. PubMed ID: 9166485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer-related anemia: clinical review and management update.
    Hurter B; Bush NJ
    Clin J Oncol Nurs; 2007 Jun; 11(3):349-59. PubMed ID: 17623620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Erythropoietin in hematology and oncology. I. Chronic anemia in malignant disease and the pharmacology of erythropoietin].
    Adam Z; Krejcí M; Vorlícek J
    Vnitr Lek; 1996 Apr; 42(4):285-9. PubMed ID: 8693717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant human erythropoietin in the treatment of cancer-related or chemotherapy-induced anaemia in patients with solid tumours.
    Nowrousian MR
    Med Oncol; 1998 Aug; 15 Suppl 1():S19-28. PubMed ID: 9785333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Tumor anemia. Overview of the role of human recombinant erythropoietin (r-hu-EPO) in treatment of tumor anemia].
    Monnerat C; Leyvraz S
    Praxis (Bern 1994); 1999 Jan; 88(5):178-88. PubMed ID: 10067375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of anemia in patients with tumors].
    Tesarová P; Kvasnicka J
    Cas Lek Cesk; 1995 Oct; 134(20):647-50. PubMed ID: 7489579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anemia in the critically ill.
    Shander A
    Crit Care Clin; 2004 Apr; 20(2):159-78. PubMed ID: 15135458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of life: subjective and objective improvements with recombinant human erythropoietin therapy.
    Lundin AP
    Semin Nephrol; 1989 Mar; 9(1 Suppl 1):22-9. PubMed ID: 2648517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in anemic cancer patients.
    Beguin Y
    Haematologica; 2002 Nov; 87(11):1209-21. PubMed ID: 12414352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erythropoietin and chronic lymphocytic leukemia.
    Mauro FR; Gentile M; Foa R
    Rev Clin Exp Hematol; 2002; Suppl 1():21-31. PubMed ID: 12735212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anemia and quality of life in cancer patients: impact of transfusion and erythropoietin.
    Thomas ML
    Med Oncol; 1998 Aug; 15 Suppl 1():S13-8. PubMed ID: 9785332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anemia therapy: individual benefit and societal cost.
    Denton TA; Diamond GA; Matloff JM; Gray RJ
    Semin Oncol; 1994 Apr; 21(2 Suppl 3):29-35. PubMed ID: 8202723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of initial resistance of erythropoiesis to treatment with recombinant human erythropoietin. Results of a multicenter trial in patients with end-stage renal disease.
    Kühn K; Nonnast-Daniel B; Grützmacher P; Grüner J; Pfåffl W; Baldamus CA; Scigalla P
    Contrib Nephrol; 1988; 66():94-103. PubMed ID: 3292152
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.